Enhanced Investments - Financial Portal

Lilly Highlights the Evolution of Its Dermatology Portfolio at Annual American Academy of Dermatology Meeting (AAD)

Published: 2020-06-12 19:00:00 ET

Data from Taltz®, baricitinib, mirikizumab and lebrikizumab underscore Lilly's commitment to discover and develop medicines for patients living with dermatological conditions

INDIANAPOLIS, June 12, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it will present new data from Taltz® (ixekizumab), Olumiant® (baricitinib), mirikizumab and lebrikizumab at the virtual American Academy of Dermatology (AAD) meeting. The data being highlighted at this year's virtual conference include the latest therapeutic data available in dermatological conditions such as psoriasis and atopic dermatitis (AD). Lilly will present 24 e-Posters, including 14 for Taltz, five for baricitinib, three for mirikizumab and two for lebrikizumab.

"At Lilly, we discover and develop new medicines because we want to help people get better and feel better," said Lotus Mallbris, M.D., Ph.D., vice president of immunology development at Lilly. "We're pleased to share new data from our dermatology pipeline at the virtual AAD meeting because we believe our medicines have the potential to help people living with dermatological conditions."

Lilly announced earlier this year that it would be expanding its dermatology portfolio through the acquisition of Dermira, a biopharmaceutical company dedicated to developing new medicines for chronic skin conditions. This acquisition reinforces Lilly's commitment to dermatology and creating new medicines for those living with skin-related diseases. Through the virtual conference, Lilly will be sharing long term data from Taltz clinical trials on itch, skin pain and health related quality of life for patients with moderate to severe plaque psoriasis who have been on the medicine for up to five-years of continuous treatment. Additional new study results will be disclosed exploring, through drug survival, the effectiveness of Taltz in the real-world setting; health economic data associated with Taltz cumulative clinical benefit will also be presented.

Data being presented on baricitinib support the medicine's potential to be a treatment option for adult patients with moderate to severe AD. Highlights of the data being presented at this year's AAD meeting include additional results from BREEZE-AD1 and BREEZE-AD2, Lilly's Phase 3 trials that are part of the baricitinib development program to support global submissions for baricitinib as a treatment for AD.

Lilly will also highlight Phase 2 safety and efficacy data from its investigational medicine mirikizumab in patients with moderate to severe plaque psoriasis. In addition, Lilly will be highlighting data surrounding the investigational therapy lebrikizumab and results from its Phase 2b studies, which is currently being measured in adult patients with moderate to severe AD.

For more information about this year's virtual AAD meeting, please visit https://www.aad.org/member/meetings-education/aadvmx.

Taltz Data

e-Posters

Indirect comparisons in psoriasis: implications for clinical practice (Presenting Authors: Kristian Reich, Alexander Nast, Richard Warren, Matthias Augustin, Christopher Schuster, Daniel Saure and Carle Paul) Abstract: 15431
Speed of Improvement in Genital Psoriasis, Genital Itch, Sexual Impact, and Health-Related Quality of Life in Patients with Moderate-to-Severe Genital Psoriasis Treated with Ixekizumab (Presenting Authors: Joseph F. Merola, Lyn Guenther, Peter Foley, Russel Burge, Kyoungah See, Missy McKean-Matthews, Gaia Gallo and Caitriona Ryan) Abstract: 14157
Patient-reported outcomes in a head-to-head, randomized, double-blinded clinical trial of ixekizumab and guselkumab in patients with moderate-to-severe plaque psoriasis (Presenting Authors: Andrew Blauvelt, Catherine Maari, Alice Gottlieb, Hany Elmaraghy, So Young Park, Renata Gontijo Lima, Russel Burge, Gaia Gallo, Lisa Renda and Jerry Bagel) Abstract: 14152
Sustained Improvements in Itch, Skin Pain, and Health-Related Quality of Life through 5 years of Treatment with Ixekizumab in Patients with Moderate-to-Severe Plaque Psoriasis (Presenting Authors: Melinda Gooderham, Boni Elewski, Mathias Augustin, Lars Iversen, Hideshi Torii, Russel Burge, Baojin Zhu, Gaia Gallo, Joe Eastman and Peter Foley) Abstract: 14159
Efficacy Of Ixekizumab Versus Adalimumab In Patients with Psoriatic Arthritis and Nail Involvement: Week-24 Post-Hoc Analysis of A Multicenter, Randomized, Open-Label Study (Presenting Authors: Saxon Smith, Lars Erik Kristensen, Christopher Schuster, Christophe Sapin, Soyi Liu Leage, Elisabeth Riedl, Kristian Reich and Phoebe Rich) Abstract: 13771
Psoriasis Patients Treated With Ixekizumab Were Maintained Longer On Monotherapy Compared To Other Biologics In Real-World Clinical Practice Settings: Results From IBM Marketscan® Databases (Presenting Authors: Mark Lebwohl, Andrew Blauvelt, Baojin Zhu, Russel Burge, Mwangi James Murage and Craig Leonardi) Abstract: 15984
Ixekizumab is Superior to Placebo for the Treatment of Nail, Scalp, and Palmoplantar Psoriasis in Pediatric Patients with Moderate-to-Severe Plaque Psoriasis (Presenting Authors: Amy Paller, Gabriel Alejandro Magariños, Andreas Pinter, Jennifer Cather, Mark Lebwohl, Stuart Keller, Claudia Rodriguez Capriles, Gaia Gallo, Emily Heredia, Lingnan Li and Kim Papp) Abstract: 14161
Treatment Goals of Patients with Psoriasis as assessed by the Patient Benefit Index: Results of a National Psoriasis Foundation Survey (Presenting Authors: April Armstrong, Emily Edson-Hereda, Baojin Zhu, David Shrom, Russel Burge, Stacie Bell, Jeffery Crowley and Stacy Smith) Abstract: 13877
Cost Per Cumulative Clinical Benefit of Biologic Therapies for Patients with Plaque Psoriasis (Presenting Authors: Richard B. Warren, Russel Burge, Baojin Zhu, William Malatestinic, Alan Brnabic, David Shrom, Jiaying Guo and Andrew Blauvelt) Abstract: 14162
Long-term Treatment Effects of Ixekizumab among Psoriasis Patients Who Achieved Early High Level Treatment Outcomes in a Real-World Setting: Results from a Single US Dermatology Referral Practice (Presenting Authors: Craig Leonardi, Rei Tao, Solmaz Setayeshgar, Sisi Wang, Suzanne McMullen, Russel Burge, Baojin Zhu and William N Malatestinic) Abstract: 14216
Achieving a PASI 50 at 2 weeks was associated with better long term clinical outcomes and low discontinuation: a subgroup analysis of a phase 3 trial of ixekizumab and etanercept in moderate to severe psoriasis (Presenting Authors: Rosmarin, Gorelick, Smith, Shrom, Burge, See, Mckean, Ridenour and Lin) Abstract: 13876
Ixekizumab demonstrated longer medication persistence than other biologics in the treatment of psoriasis patients: Results from IBM MarketScan® database (Presenting Authors: Andrew Blauvelt, Craig Leonardi, Baojin Zhu, Joe Eastman, William Malatestinic, Jiaying Guo, Russel Burge, David Shrom, Mwangi Murage and Mark Lebwohl) Abstract: 16007
Treatment Satisfaction in Patients with Moderate-to-Severe Psoriasis by Drug Class and Dose Frequency: Results from a United States Web-Based Survey (Presenting Authors: April Armstrong, David Shrom, Russel Burge, Baojin Zhu and Joseph Gorelick) Abstract: 14160
Pharmacokinetics, Safety and Efficacy of Ixekizumab in Chinese Patients with Plaque Psoriasis: results from a Phase 1, Single- and Multiple-Dose Study (Presenting Authors: Jie Zheng, Min Zheng, Xiang Chen, Kimberley Jackson, Fan Yang and Feng Wang) Abstract: 14066

Baricitinib Data

e-Posters

Patients' Characteristics and Treatment Strategies in Pediatric Patients Diagnosed with Atopic Dermatitis Versus Eczema – A Real-World Retrospective Cohort Study (Presenting Authors: Natalie N. Boytsov, Orin M. Goldblum, Magdaliz Gorritz, William N. Malatestinic, Xiang Zhang, Xin Wang and Rolin L. Wade) Abstract: 15342
Impact of Baricitinib On Patient-Reported Skin Symptoms, Itch, And Quality of Life in Adult Patients with Moderate-To-Severe Atopic Dermatitis and An Inadequate Response to Topical Therapies from Phase 3 Trials, BREEZE-AD1 and BREEZE-AD2 (Presenting Authors: Peter Lio, Audrey Nosbaum, Tracy Cardelo, Amy DeLozier, Margaret Gamalo, Susan Ball and Thomas Bieber) Abstract: 15054
Baricitinib, An Oral, Reversible Janus Kinase -1 And -2 Inhibitor, For Atopic Dermatitis: Head and Neck Response Across 2 Phase 3 Studies (Presenting Authors: Eric Simpson, Emma Guttman-Yassky, Robert Bissonnette, Na Lu, Yun-Fei Chen, Fabio Nunes, Maria Jose Rueda and Carle Paul) Abstract: 15059
Safety of Baricitinib in Patients with Atopic Dermatitis: Results of Pooled Data from Two Phase 3 Monotherapy Randomized, Double-Blind, Placebo-Controlled 16-week Trials (BREEZE-AD1 and BREEZE-AD2) (Presenting Authors: Kristian Reich, Jean Philippe Lacour, Antonio Constanzo, Dennis R Brinker, Maria Jose Rueda, Fabio Nunes, Maher Issa, Amy Paller and Jonathan I. Silverberg) Abstract: 15057
The Effect of Baricitinib On Daily and Workplace Activity from Phase 3 Trials, BREEZE-AD1 and BREEZE-AD2, In Adult Patients with Moderate-To-Severe Atopic Dermatitis (Presenting Authors: Lawrence Eichenfield, Jonathan Silverberg, Jose Manuel Carrascosa, Diana Rubel, Steven Watts, Marta Casillas, Amy M. DeLozier, Evangeline Pierce and Matthias Augustin) Abstract: 15058

Mirikizumab Data

e-Posters

Efficacy and Safety of Mirikizumab in Patients with Moderate-to-Severe Plaque Psoriasis: 104-Week Results from a Randomized Phase 2 Study (Authors: Robert Bissonnette, Catherine Maari, Alan Menter, Chika Ohata, Kim Papp, Jay Tuttle, Paul Klekotka, Karen Liu, Dipak Patel and Kristian Reich) Abstract: 15328
Impact of Mirikizumab Maintenance Dosing at Week 104 on Health-related Quality of Life in Patients Who Had

Enhanced Investments, Inc.
329 South Oyster Bay Road #2085
Plainview, NY 11803
team@eninvs.com

Important disclosures

Performance results were prepared by Enhanced Investments, and have not been compiled, reviewed or audited by an independent accountant. Performance estimates are subject to future adjustment and revision. Investors should be aware that a loss of investment is possible. Account holdings are for illustrative purposes only and are not investment recommendations. Additional information, including (i) the calculation methodology; and (ii) a list showing the contribution of each holding to the portfolio’s performance during the time period will be provided upon request.
All statements made via social media sites sponsored or maintained by Enhanced Investments and its affiliates are for informational purposes only and do not constitute a comprehensive description of Enhanced Investments' investment advisory services.
Certain investments are not suitable for all investors. Before investing, consider your investment objectives and applicable fees. The rate of return on investments can vary widely over time, especially for long term investments. Investment losses are possible, including the potential loss of all amounts invested. Information provided by Enhanced Investments is for informational and general educational purposes only and is not investment or financial advice.

Nothing on this website should be considered an offer, solicitation of an offer, or advice to buy or sell securities.
Past performance is no guarantee of future results. Any historical returns, expected returns [or probability projections] are hypothetical in nature and may not reflect actual future performance.
All the strategies assume investments in equity invstrumenta only and are more relevant for "agressive investment profile". Eastern European flagship strategy assumes using up to 20% leverage of total portfolio. GlobalCommodities and US Growth strategy currently assume no leverage.
Results for the Enhanced Investments strategies as compared to the performance of Illustrative Benchmarks is for informational purposes only. Our investment program does not mirror that of the Illustrative Benchmarks and the volatility may be materially different from the volatility of Illustrative Benchmarks. Reference or comparison to an Illustrative Benchmark does not imply that strategies of Enhanced Investments will be constructed in the same way as the Illustrative Benchmark or achieve returns, volatility, or other results similar to those of the Illustrative Benchmark. The S&P 500 is an unmanaged market capitalization-weighted index of 500 common stocks chosen for market size, liquidity, and industry group representation to represent U.S. equity performance.
Performance results were prepared by Enhanced Investments, and have not been compiled, reviewed or audited by an independent accountant. Performance estimates are subject to future adjustment and revision. Investors should be aware that a loss of investment is possible. Account holdings are for illustrative purposes only and are not investment recommendations. Additional information, including (i) the calculation methodology; and (ii) a list showing the contribution of each holding to the portfolio’s performance during the time period will be provided upon request.
All statements made via social media sites sponsored or maintained by Enhanced Investments and its affiliates are for informational purposes only and do not constitute a comprehensive description of Enhanced Investments' investment advisory services.
Certain investments are not suitable for all investors. Before investing, consider your investment objectives and applicable fees. The rate of return on investments can vary widely over time, especially for long term investments. Investment losses are possible, including the potential loss of all amounts invested. Information provided by Enhanced Investments is for informational and general educational purposes only and is not investment or financial advice.